Human Genetic Variation Alters Anthrax Toxin Sensitivity
Martchenko, Candille et al., PNAS
Researchers at Stanford University School of Medicine show that genetic variation affecting capillary morphogenesis gene 2, or CMG2, dramatically alters toxin sensitivity in humans. In its analysis, the team reports on "a CMG2 single-nucleotide polymorphism occurring frequently in African and European populations [that they found] independently altered toxin uptake." The group goes on to suggest "testing of genomically characterized human cell populations may offer a broadly useful strategy for elucidating effects of genetic variation on infectious disease susceptibility."
FDA Tells Congress it is Mulling Strategies to Regulate DTC Genetic Tests as Medical Devices
July 28, 2010
At a congressional hearing on DTC genomics this week, an FDA official acknowledged that the agency had waited too long to regulate this rapidly growing field. The agency said it is considering an "out-of-the-box approach" toward overseeing the consumer genomics industry.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- DTC Genomics Firms Say They Want to Comply with FDA Regs but Maintain Direct Access
March 16, 2011 / Pharmacogenomics Reporter - CDC Advises Docs to Inform Patients of Limitations of DTC Gene Scans
August 11, 2010 / Pharmacogenomics Reporter - Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS
October 19, 2011 / Pharmacogenomics Reporter - Researchers ID Gastric Cancer Biomarker Aimed for Use in DTC Tests in US, China
May 6, 2011 / ProteoMonitor - ASU Biodesign Scientists Hope to Apply Direct-to-Consumer Model to Proteomics Testing
February 4, 2011 / ProteoMonitor